Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

How in silico trials are making personalized medicine a reality

WWW.OUTSOURCING-PHARMA.COM

January 11, 2019
AI & Machine Learning, Oncology, Precision Medicine

The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO. (outsourcing-pharma.com)

Genetic component is complicating clinical trials, esp oncology

medcitynews.com

January 11, 2019
Clinical trials, Oncology, Precision Medicine

Genetics are playing a growing role in clinical trials, as more therapies in development are targeted to the underlying cause of a disease. Nearly half of all therapies in clinical trials, and 73% of oncology trials, are collecting biomarker and genetic data. Adding genetic testing can complicate a study, and the authors recommend that sponsors provide trained genetic counselors as a resource to their investigators. (MedCityNews)

Rep. Rose DeLauro introduces the “Recall Unsafe Drugs Act”

raps.org

March 1, 2017
Clinical development, Precision Medicine

Although the FDA is supposed to intervene when safety concerns arise with an existing pharmaceutical or over-the-counter product, they do not have the authority to require companies to stop marketing unsafe products. This loophole allows companies to refuse FDA’s calls to remove their pharmaceuticals from the market because they are unsafe.  Rep. Rose DeLauro (D-CT) introduced the “Recall Unsafe Drugs Act” that will give the FDA mandatory recall authority over drugs and homeopathic products. (Regulatory Focus)

Current Feature

San Diego Tech Startup, CureMatch, is Revolutionizing Precision Medicine in Oncology

January 16, 2017
Innovation, Precision Medicine

-by Madison Arenchild, special to Clinical Research Currents For medical professionals, making course of treatment decisions for the 1.6 million new cancer diagnoses made each year in the US alone is an extremely difficult undertaking. This decision is further complicated by the heterogeneous nature of tumor make-up and behavior and Read more

Biomarkers triple clinical trial success rate, says report

www.outsourcing-pharma.com

June 5, 2016
Clinical science, Precision Medicine

A recent study of clinical drug development success rates found that biomarker-enabled drug programs are three times more likely to reach approval. (Outsourcing-Pharma.com)

Genomic and Precision Medicine on Coursera

www.coursera.org

June 4, 2016
Education, Precision Medicine

This free online 7-week course aims to educate the health care workforce in the field of genomic and precision medicine. Materials also available through the UCSF website.

Current Feature

National leaders in precision medicine speak at SDCRN meeting

November 25, 2015
Precision Medicine

Advancing Precision Medicine: Genomics, Metabolomics, and Clinical Trials By Dr. Roberta Alexander San Diego, CA. October 12, 2015 The San Diego Clinical Research Network (SDCRN) organized another great event on October 12. It was held in the Alexandria Building of BIOCOM in the Torrey Mesa area. The building and the Read more

Scientists urge national initiative on microbiomes

www.nytimes.com

November 11, 2015
Precision Medicine

Scores of leading scientists on Wednesday urged the creation of a major initiative to better understand the microbial communities critical to both human health and every ecosystem.  (New York Times online)

Human Longevity appoints head of regulatory affairs and policy

news.centerwatch.com

November 10, 2015
Precision Medicine, Regulatory

Human Longevity (HLI), the genomics-based, technology-driven company, has announced that Sally Howard, J.D., has been hired as head of regulatory affairs and policy.  Howard, who has more than two decades of health policy and regulatory expertise, will lead all efforts related to federal and state regulatory oversight for HLI. (CenterWatch News Online)

Seek 1 million U.S. citizens

www.nature.com

November 9, 2015
Precision Medicine, Regulatory

The U.S. National Institutes of Health (NIH) will start enrolling 1 million or more U.S. citizens as the first key step to implementing President Obama’s nationwide Precision Medicine Initiative (PMI). Plans for the clinical research cohort were outlined in September by the NIH Advisory committee. ($. Nature Biotechnology)

  • 1
  • 2
  • Next Page »

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2023 Clinical Research Currents · All Rights Reserved